Abstract
Coronary artery stenting is currently the most frequently performed percutaneous coronary intervention for the treatment of coronary artery disease. Recently, drug- eluting stents, loaded with anti-inflammatory, anti-migratory, antiproliferative or pro-healing drugs, have revolutionized the management of coronary artery disease by markedly reducing in-stent restenosis. Despite the excellent short- and mid-term results of randomized controlled trials observed with drugeluting stents, there remain a number of unresolved issues and valid concerns about long-term safety and efficacy of this revolutionary technology. Important safety issues such as thrombosis, late stent malapposition, aneurysm formation, edge effect, late inflammation due to choice of polymer used to bind the drug, the release of toxins, and potential interactions with brachytherapy and drugs have not been completely addressed. This review article evaluates current available scientific evidence on the various safety issues related to the use of drug-eluting stents.
Keywords: Stent, in-stent restenosis, percutaneous coronary intervention, drug-eluting stents, thrombosis
Current Drug Safety
Title: Safety of Drug Eluting Stents: Current Concerns and Controversies
Volume: 2 Issue: 3
Author(s): Shahzad G. Raja and Geoffrey A. Berg
Affiliation:
Keywords: Stent, in-stent restenosis, percutaneous coronary intervention, drug-eluting stents, thrombosis
Abstract: Coronary artery stenting is currently the most frequently performed percutaneous coronary intervention for the treatment of coronary artery disease. Recently, drug- eluting stents, loaded with anti-inflammatory, anti-migratory, antiproliferative or pro-healing drugs, have revolutionized the management of coronary artery disease by markedly reducing in-stent restenosis. Despite the excellent short- and mid-term results of randomized controlled trials observed with drugeluting stents, there remain a number of unresolved issues and valid concerns about long-term safety and efficacy of this revolutionary technology. Important safety issues such as thrombosis, late stent malapposition, aneurysm formation, edge effect, late inflammation due to choice of polymer used to bind the drug, the release of toxins, and potential interactions with brachytherapy and drugs have not been completely addressed. This review article evaluates current available scientific evidence on the various safety issues related to the use of drug-eluting stents.
Export Options
About this article
Cite this article as:
Raja G. Shahzad and Berg A. Geoffrey, Safety of Drug Eluting Stents: Current Concerns and Controversies, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668918
DOI https://dx.doi.org/10.2174/157488607781668918 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Antiplatelet Agents in the Management of Patients Receiving Intracardiac Closure Devices
Current Pharmaceutical Design Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Antimicrobial Treatment to Impair Expansion of Abdominal Aortic Aneurysm (AAA): A Systematic Review of the Clinical Evidence
Current Vascular Pharmacology The Clinical Usefulness of Nuclear Medicine Techniques in the Diagnosis of Vascular Graft Infections
Current Molecular Imaging (Discontinued) Beta-blockers in Intensive Care Medicine: Potential Benefit in Acute Brain Injury and Acute Respiratory Distress Syndrome
Recent Patents on Cardiovascular Drug Discovery Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich
Recent Patents on Cardiovascular Drug Discovery Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Coarctation of the Aorta - An Evolution of Therapeutic Options
Current Cardiology Reviews Underlying Mechanisms and Potential Therapeutic Molecular Targets in Blood-Brain Barrier Disruption after Subarachnoid Hemorrhage
Current Neuropharmacology Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Cerebrovascular Ultrasonography for Selecting Patients for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Ruptured Bronchial Artery Aneurysm Treated With Aortic Stent Graft and Aneurysm Embolization
Current Medical Imaging Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery Complex Inheritance for Susceptibility to Sudden Cardiac Death
Current Pharmaceutical Design